Patents by Inventor László Vígh

László Vígh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190192336
    Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder medi
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Inventors: Ferenc FÜLÖP, László VÍGH, Zsolt TÖRÖK, Botond PENKE, Ibolya HORVÁTH, Gábor BALOGH, Sándor BERNÁTH, Ákos HUNYA
  • Patent number: 10258498
    Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder medi
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: April 16, 2019
    Assignee: Richter Gedeon NYRT.
    Inventors: Ferenc Fülöp, László Vigh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
  • Publication number: 20150366852
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
    Type: Application
    Filed: June 23, 2015
    Publication date: December 24, 2015
    Inventors: Peter Literati Nagy, Jesse Roth, Zoltan Szilvassy, Kalman Tory, Michael Brownstein, Kálmán Takács, Laszlo Vigh, József Mandl, Balázs Sümegi, Sandor Bernath, Attila Kolonics, Gábor Balogh, Janos Egri
  • Publication number: 20140315893
    Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder medi
    Type: Application
    Filed: November 22, 2012
    Publication date: October 23, 2014
    Inventors: Ferenc Fülöp, László Vígh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
  • Publication number: 20100311719
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
    Type: Application
    Filed: August 17, 2010
    Publication date: December 9, 2010
    Inventors: Péter Literáti Nagy, Jesse Roth, Zoltán Szilvássy, Kálmán Tory, Mike Brownstein, Kálmán Takács, László Vígh, József Mandl, Balázs Sümegi, Sándor Bernáth, Attila Kolonics, Gábor Balogh, János Egri
  • Publication number: 20100267711
    Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.
    Type: Application
    Filed: June 25, 2010
    Publication date: October 21, 2010
    Applicant: CytRx Corporation
    Inventors: László Vígh, Péter Literáti Nagy, Jenó Szilbereky, László Ürögdi, Andrea Jednákovits, László Jaszlits, Katalin Bíró, Ede Màrvànyos, Mihály Barabás, Erzsébet Hegedüs, László Korányi, Mária Kürthy, Gábor Balogh, Ibolya Horváth, Zsolt Török, Éva Udvardy, György Dormán, Dénes Medzihradszky, Bea Mézes, Eszter Kovács, Ernó Duda, Beatrix Farkas, Attila Glatz
  • Patent number: 7763601
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime (BGP-15) or a pharmaceutically suitable acid addition salt thereof can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight gain.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: July 27, 2010
    Assignee: N-Gene Research Laboratories, Inc.
    Inventors: Péter Literáti Nagy, Zoltán Szilvássy, Kálmán Tory, László Vígh, Kálmán Takács, József Mandl, Balázs Sümegi, Sándor Bernáth, Attila Kolonics, Gábor Balogh, János Egri
  • Patent number: 7745465
    Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: June 29, 2010
    Assignee: CytRx Corporation
    Inventors: László Vígh, Péter Literáti Nagy, Jenö Szilbereky, László Ürögdi, Andrea Jednákovits, László Jaszlits, Katalin Bíró, Ede Márványos, Mihály Barabás, Erzsébet Hegedüs, László Korányi, Mária Kürthy, Gábor Balogh, Ibolya Horváth, Zsolt Török, Éva Udvardy, György Dormán, Dénes Medzihradszky, Bea Mézes, Eszter Kovács, Ernö Duda, Beatrix Farkas, Attila Glatz
  • Publication number: 20090281143
    Abstract: O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce overweight or obesity and, preferably, reduce one or more unfavourable psychiatric side effects of the cannabinoid CB1 receptor antagonist.
    Type: Application
    Filed: December 10, 2008
    Publication date: November 12, 2009
    Inventors: Peter Literati Nagy, Zoltan Szilvassy, Kalman Tory, Attila Kolonics, Sandor Bernath, Laszlo Vigh, Jesse Roth, G. Alexander Fleming, Michael Brownstein, Janos Egri
  • Publication number: 20090214677
    Abstract: An extract of a part of a Solidago species, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient is used for the regeneration of the organism of a mammal after long-lasting immobilization, anorexia, states following a disease or accompanied by weight loss as well as for muscle development or muscle growth during muscle developing training, treatment of muscular strain and adaptation to high-altitude as well as for the prevention or treatment of neurodegenerative diseases and/or motility disorders of the gastrointestinal system.
    Type: Application
    Filed: August 30, 2006
    Publication date: August 27, 2009
    Applicant: ELSO MAGYAR BIODROG KUTATÓ ÉS FEJLESZTO KFT
    Inventors: Péter Literati Nagy, Kalman Tory, Attila Kolonics, Agnes Keri, Lajos Laszlo, Laszlo Jaszlits, Agnes Bajza, Sandor Bernath, Laszlo Vigh, Tibor Bodnar, Janos Egri
  • Publication number: 20090130234
    Abstract: The invention refers to the use of an extract of a part of a Solidago species, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active agent for the preparation of a pharmaceutical composition suitable for the treatment of diabetic periodontitis.
    Type: Application
    Filed: October 10, 2006
    Publication date: May 21, 2009
    Inventors: Peter Literati Nagy, Zsolt Lohinai, Kalman Tory, Attila Kolonics, Agnes Keri, Orsolya Rigo, Andras Huszak, Balazs Zahonyi, Sandor Bernath, Laszlo Vigh, Tibor Bodnar, Jonos Egri
  • Publication number: 20080108673
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight.
    Type: Application
    Filed: March 19, 2007
    Publication date: May 8, 2008
    Inventors: Peter Literati Nagy, Zoltan Szilvassy, Kalman Tory, Laszlo Vigh, Kalman Takacs, Jozsef Mandl, Balazs Sumegi, Sandor Bernath, Attila Kolonics, Gabor Balogh, Janos Egri
  • Publication number: 20080108602
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
    Type: Application
    Filed: March 19, 2007
    Publication date: May 8, 2008
    Inventors: Peter Literati Nagy, Jesse Roth, Zoltan Szilvassy, Kalman Tory, Mike Brownstein, Kalman Takacs, Laszlo Vigh, Jozsef Mandi, Balazs Sumegi, Sandor Bernath, Attila Kolonics, Gabor Balogh, Janos Egri
  • Patent number: 7148239
    Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: December 12, 2006
    Assignee: CytRx Corporation
    Inventors: László Vígh, Péter Literáti Nagy, Jenó Szilbereky, László Ürögdi, Andrea Jednákovits, László Jaszlits, Katalin Bíró, Ede Márványos, Mihály Barabás, Erzsébet Hegedüs, László Korányi, Mária Kürthy, Gábor Balogh, Ibolya Horváth, Zsolt Török, Éva Udvardy, György Dormán, Dénes Medzihradszky, Bea Mézes, Eszter Kovács, Ernó Duda, Beatrix Farkas, Attila Glatz
  • Patent number: 6884424
    Abstract: The invention relates to methods for prevention and/or treatment of skin lesions caused by exposure to ultraviolet radiation. Exemplary condition that can be prevented or treated are actinic keratosis, dry skin, polymorphic light exanthema, photopathology, photo-allergy, solar atrophy, stria migrans, elastoma diffusum, X-ray dermatitis, gouty polychondritis and decubitis ulcer.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: April 26, 2005
    Assignee: N-Gene Research Laboratories Inc.
    Inventors: Bea Farkas, Peter Literati Nagy, Agnes Vadasz, Laszlo Vigh
  • Publication number: 20040067940
    Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.
    Type: Application
    Filed: July 10, 2003
    Publication date: April 8, 2004
    Applicant: Biorex Research & Development Co.
    Inventors: Laszlo Vigh, Peter Literati Nagy, Jeno Szilbereky, Laszlo Urogdi, Andrea Jednakovits, Laszlo Jaszlits, Katalin Biro, Ede Marvanyos, Mihaly Barabas, Erzsebet Hegedus, Laszlo Koranyi, Maria Kurthy, Gabor Balogh, Ibolya Horvath, Zsolt Torok, Eva Udvardy, Gyorgy Dorman, Denes Medzihradszky, Bea Mezes, Eszter Kovacs, Erno Duda, Beatrix Farkas, Attila Glatz
  • Publication number: 20040019103
    Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II).
    Type: Application
    Filed: July 10, 2003
    Publication date: January 29, 2004
    Applicant: Biorex Research & Development Co.
    Inventors: Laszlo Vigh, Peter Literati Nagy, Jeno Szilbereky, Laszlo Urogdi, Andrea Jednakovits, Laszlo Jaszlits, Katalin Biro, Ede Marvanyos, Mihaly Barabas, Erzsebet Hegedus, Laszlo Koranyi, Maria Kurthy, Gabor Balogh, Ibolya Horvath, Zsolt Torok, Eva Udvardy, Gyorgy Dorman, Denes Medzihradszky, Bea Mezes, Eszter Kovacs, Erno Duda, Beatrix Farkas, Attila Glatz
  • Patent number: 6653326
    Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively; an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxyl amine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: November 25, 2003
    Assignee: Biorex Research & Development Co.
    Inventors: László Vígh, Péter Literáti Nagy, Jenó Szilbereky, László Ürögdi, Andrea Jednákovits, László Jaszlits, Katalin Bíró, Ede Màrvànyos, Mihály Barabás, Erzsébet Hegedüs, László Korányi, Mária Kürthy, Gábor Balogh, Ibolya Horváth, Zsolt Török, Éva Udvardy, György Dormán, Dénes Medzihradszky, Bea Mézes, Eszter Kovács, Ernö Duda, Beatrix Farkas, Attila Glatz
  • Patent number: 6458371
    Abstract: A novel cosmetic composition comprising a known hydroximic acid derivative as the active ingredient, and conventional carriers of the cosmetic composition are disclosed. The cosmetic composition of the invention is suitable for the prevention and/or reduction of the photoaging processes of the skin exposed to UV radiation.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: October 1, 2002
    Assignee: Medgene, Limited
    Inventors: Bea Farkas, Peter Literati Nagy, Agnes Vadasz, Laszlo Vigh
  • Publication number: 20020131938
    Abstract: The invention relates to methods for prevention and/or treatment of skin lesions caused by exposure to ultraviolet radiation. Exemplary condition that can be prevented or treated are actinic keratosis, dry skin,polymorphic light exanthema, photopathology, photo-allergy, solar atrophy, stria migrans, elastoma diffusum, X-ray dermatits, gouty polychondritis and decubitis ulcer.
    Type: Application
    Filed: December 7, 2001
    Publication date: September 19, 2002
    Inventors: Bea Farkas, Peter Literati Nagy, Agnes Vadasz, Laszlo Vigh